Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsabiv in pediatric secondary hyperparathyroidism
NCT02833857Phase 1Completed
- Sponsor
- Amgen
- Start
- Mar 2017
- Primary completion
- Oct 2018
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of etelcalcetide in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Primary endpoints: Treatment-emergent Adverse Events at 30 days, Serum Corrected Calcium Concentration at 30 days and 11 more. Started Mar 2017; status: completed.
02
Drugs
etelcalcetide
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT02833857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833857.